Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9758582
SERIAL NO

15145135

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOCON LIMITEDBANGALORE 560 100 KARNATAKA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Govindappa, Nagaraj Karnataka, IN 18 82
Sastry, Kedarnath Karnataka, IN 10 58
Soares, Maria Melina Karnatake, IN 12 66

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00